{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:19:46Z","timestamp":1784661586380,"version":"3.55.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Sodium glucose cotransporter-2 inhibitors (SGLT2i) have been found to have a range of benefits, including improving obesity and insulin resistance, hyperuricemia, hypertension, hyperlipidemia, and other metabolic disorders. Initially used for the hypoglycemic effects, they are now found to benefit atherosclerotic cardiovascular disease and chronic kidney disease. Additionally, SGLT2i has been found to have multiple functions, such as improving liver metabolism, affecting brain function, protecting islet \u03b2 cell function, anti-tumor, and affecting immune system function. This review provides an overview of the protective effects of SGLT2i on different organs and tissues, as well as the potential mechanisms underlying the functional improvement induced by SGLT2i in recent years.<\/jats:p>","DOI":"10.3389\/fendo.2025.1641699","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:43Z","timestamp":1759119163000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Multi-dimensional roles of sodium-glucose cotransporter 2 inhibitors: beyond hypoglycemic and cardiorenal protection"],"prefix":"10.3389","volume":"16","author":[{"given":"Siyu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2020.1841281","article-title":"The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection","volume":"53","author":"Brown","year":"2021","journal-title":"Ann Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052812","article-title":"Sodium glucose cotransporter-2 inhibitors: spotlight on favorable effects on clinical outcomes beyond diabetes","volume":"23","author":"\u010cert\u00edkov\u00e1 Ch\u00e1bov\u00e1","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.09.011","article-title":"Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study","volume":"33","author":"Kasichayanula","year":"2011","journal-title":"Clin Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: A randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"B11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.diabet.2015.10.003","article-title":"Effect of canagliflozin on liver function tests in patients with type 2 diabetes","volume":"42","author":"Leiter","year":"2016","journal-title":"Diabetes Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2337\/figshare.19241664","article-title":"The SGLT2 inhibitor dapagliflozin increases the oxidation of ingested fatty acids to ketones in type 2 diabetes","volume":"45","author":"Herring","year":"2022","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4985","article-title":"Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Li","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111513","article-title":"In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia","volume":"22","author":"H\u00fcttl","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20205237","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","volume":"20","author":"Jojima","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.589273","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"G235","DOI":"10.1152\/ajpgi.00029.2024","article-title":"SGLT2 inhibition leads to a restoration of hepatic and circulating metabolites involved in the folate cycle and pyrimidine biosynthesis","volume":"327","author":"Mendez Espinoza","year":"2024","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.827033","article-title":"The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male zucker diabetic fatty rats towards a protective profile","volume":"13","author":"Arag\u00f3n-Herrera","year":"2022","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9040353","article-title":"Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH","volume":"9","author":"Hupa-Breier","year":"2021","journal-title":"Biomedicines"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0261310","DOI":"10.1371\/journal.pone.0261310","article-title":"Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model","volume":"17","author":"Morishita","year":"2022","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050799","article-title":"Empagliflozin-enhanced antioxidant defense attenuates lipotoxicity and protects hepatocytes by promoting foxO3a- and nrf2-mediated nuclear translocation via the CAMKK2\/AMPK pathway","volume":"11","author":"Wang","year":"2022","journal-title":"Antioxids (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-024-01389-3","article-title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.039","article-title":"A TNF\u03b1\/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates nonalcoholic steatohepatitis","volume":"79","author":"Jin","year":"2023","journal-title":"J Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.apsb.2021.07.021","article-title":"Therapeutic regulation of autophagy in hepatic metabolism","volume":"12","author":"Byrnes","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed apoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30834","article-title":"The role of senescence in the development of nonalcoholic fatty liver disease and progression to nonalcoholic steatohepatitis","volume":"71","author":"Papatheodoridi","year":"2020","journal-title":"Hepatology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"111738","DOI":"10.1016\/j.biopha.2021.111738","article-title":"The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model","volume":"140","author":"Yoshioka","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00716","article-title":"Glucose-sensing in the reward system","volume":"11","author":"Koekkoek","year":"2017","journal-title":"Front Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.564708","article-title":"Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population: the Hisayama study","volume":"41","author":"Doi","year":"2010","journal-title":"Stroke"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2012.10.020","article-title":"Post-ischemic hyperglycemia exacerbates the development of cerebral ischemic neuronal damage through the cerebral sodium-glucose transporter","volume":"1489","author":"Yamazaki","year":"2012","journal-title":"Brain Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12548","article-title":"Empagliflozin attenuates transient cerebral ischemia\/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway","volume":"34","author":"Amin","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-020-01237-y","article-title":"Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia\/reperfusion injury through HIF-1\u03b1\/VEGF signaling pathway","volume":"43","author":"Abdel-Latif","year":"2020","journal-title":"Arch Pharm Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12883-018-1086-4","article-title":"Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy","volume":"18","author":"Erdogan","year":"2018","journal-title":"BMC Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2887","article-title":"Effects of the SGLT2 inhibitor dapagliflozin on energy metabolism in patients with type 2 diabetes: A randomized, double-blind crossover trial","volume":"44","author":"Op den Kamp","year":"2021","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X20666220420130109","article-title":"Insight into the cellular interactions and molecular mechanisms of ketogenic diet for comprehensive management of epilepsy","volume":"20","author":"Kumar","year":"2022","journal-title":"Curr Neuropharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092616","article-title":"Therapeutic use of the ketogenic diet in refractory epilepsy: what we know and what still needs to be learned","volume":"12","author":"Zarnowska","year":"2020","journal-title":"Nutrients"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01256.x","article-title":"A prospective study of the modified Atkins diet for intractable epilepsy in adults","volume":"49","author":"Kossoff","year":"2008","journal-title":"Epilepsia"},{"key":"B42","doi-asserted-by":"publisher","first-page":"105158","DOI":"10.1016\/j.neuint.2021.105158","article-title":"Empagliflozin nanoparticles attenuates type2 diabetes induced cognitive impairment via oxidative stress and inflammatory pathway in high fructose diet induced hyperglycemic mice","volume":"150","author":"Khan","year":"2021","journal-title":"Neurochem Int"},{"key":"B43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2434","article-title":"Empagliflozin improves cognitive impairment in frail older adults with type 2 diabetes and heart failure with preserved ejection fraction","volume":"45","author":"Mone","year":"2022","journal-title":"Diabetes Care"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-215678","article-title":"Association between use of sodium-glucose co-transporter-2 (SGLT2) inhibitors and cognitive function in a longitudinal study of patients with type 2 diabetes","volume":"87","author":"Low","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2020.03.018","article-title":"A role for sodium glucose cotransporter 2 inhibitors (SGLT2is) in the treatment of Alzheimer\u2019s disease","volume":"155","author":"Esterline","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.2174\/18715273113126660160","article-title":"Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer\u2019s disease- diabetes type 2 linkage via an enzoinformatics study","volume":"13","author":"Rizvi","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e209805","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tins.2022.03.001","article-title":"Insulin action in the brain: cell types, circuits, and diseases","volume":"45","author":"Chen","year":"2022","journal-title":"Trends Neurosci"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00498-x","article-title":"Brain insulin signalling in metabolic homeostasis and disease","volume":"17","author":"Scherer","year":"2021","journal-title":"Nat Rev Endocrinol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"398","DOI":"10.2337\/dc21-1136","article-title":"Empagliflozin improves insulin sensitivity of the hypothalamus in humans with prediabetes: A randomized, double-blind, placebo-controlled, phase 2 trial","volume":"45","author":"Kullmann","year":"2022","journal-title":"Diabetes Care"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.10.007","article-title":"Durability of protective effect of dulaglutide on pancreatic \u03b2-cells in diabetic mice: GLP-1 receptor expression is not reduced despite long-term dulaglutide exposure","volume":"44","author":"Kimura","year":"2018","journal-title":"Diabetes Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12005","article-title":"Vildagliptin preserves the mass and function of pancreatic \u03b2 cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes","volume":"15","author":"Hamamoto","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2069-9","article-title":"The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes","volume":"54","author":"Shimoda","year":"2011","journal-title":"Diabetologia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenl\u00f6f","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin treatment is associated with improved \u03b2-cell function in type 2 diabetes mellitus","volume":"103","author":"Al Jobori","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1055\/a-0664-7583","article-title":"Effect of dapagliflozin on insulin secretion and insulin sensitivity in patients with prediabetes","volume":"128","author":"Ram\u00edrez-Rodr\u00edguez","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"E258","DOI":"10.1152\/ajpendo.00267.2023","article-title":"Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes","volume":"326","author":"Jahn","year":"2024","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B60","doi-asserted-by":"publisher","first-page":"154324","DOI":"10.1016\/j.metabol.2020.154324","article-title":"Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice","volume":"111","author":"Wei","year":"2020","journal-title":"Metabolism"},{"key":"B61","doi-asserted-by":"publisher","first-page":"114009","DOI":"10.1016\/j.bcp.2020.114009","article-title":"Dapagliflozin exerts positive effects on beta cells, decreases glucagon and does not alter beta- to alpha-cell transdifferentiation in mouse models of diabetes and insulin resistance","volume":"177","author":"Tanday","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/biomedicines10020203","article-title":"Inhibition of SGLT2 preserves function and promotes proliferation of human islets cells in vivo in diabetic mice","volume":"10","author":"Karlsson","year":"2022","journal-title":"Biomedicines"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2001240","article-title":"Empagliflozin protects diabetic pancreatic tissue from damage by inhibiting the activation of the NLRP3\/caspase-1\/GSDMD pathway in pancreatic \u03b2 cells: in vitro and in vivo studies","volume":"12","author":"Liu","year":"2021","journal-title":"Bioengineered"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.838410","article-title":"Recent advances in incretin-based pharmacotherapies for the treatment of obesity and diabetes","volume":"13","author":"Tan","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00689-w","article-title":"Canagliflozin increases postprandial total glucagon-like peptide 1 levels in the absence of \u03b1-glucosidase inhibitor therapy in patients with type 2 diabetes: A single-arm, non-randomized, open-label study","volume":"10","author":"Osonoi","year":"2019","journal-title":"Diabetes Ther"},{"key":"B66","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr3112w","article-title":"Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2\/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus","volume":"9","author":"Takebayashi","year":"2017","journal-title":"J Clin Med Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.04.002","article-title":"Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells","volume":"43","author":"Solini","year":"2017","journal-title":"Diabetes Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13081","article-title":"Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic \u03b2-cells in people with type 2 diabetes","volume":"20","author":"Ahn","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"112864","DOI":"10.1016\/j.biopha.2022.112864","article-title":"Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological Malignancy in humans","volume":"149","author":"Nakachi","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int J Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Mol Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B74","doi-asserted-by":"publisher","first-page":"aat5933","DOI":"10.1126\/scitranslmed.aat5933","article-title":"Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma","volume":"10","author":"Scafoglio","year":"2018","journal-title":"Sci Transl Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.902530","article-title":"Therapeutic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin on renal cell carcinoma","volume":"23","author":"Kuang","year":"2017","journal-title":"Med Sci Monit"},{"key":"B76","doi-asserted-by":"publisher","first-page":"110821","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"BioMed Pharmacother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-021-00494-6","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro","volume":"12","author":"Yamamoto","year":"2021","journal-title":"Diabetol Int"},{"key":"B78","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1507\/endocrj.EJ19-0428","article-title":"SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation","volume":"67","author":"Komatsu","year":"2020","journal-title":"Endocr J"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.7118","article-title":"Lower risks of new-onset hepatocellular carcinoma in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors versus DPP4 inhibitors","volume":"22","author":"Chou","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B80","doi-asserted-by":"publisher","first-page":"119329","DOI":"10.1016\/j.lfs.2021.119329","article-title":"Investigation into the role of anti-diabetic agents in cachexia associated with metastatic cancer","volume":"274","author":"Bora","year":"2021","journal-title":"Life Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","article-title":"SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia","volume":"7","author":"Nasiri","year":"2019","journal-title":"Cancer Metab"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2021.02.003","article-title":"Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin","volume":"23","author":"Papadopoli","year":"2021","journal-title":"Neoplasia"},{"key":"B83","doi-asserted-by":"publisher","first-page":"e0232283","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PloS One"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413336","article-title":"Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1\u03b1 Protein synthesis via AKT\/mTOR pathway","volume":"22","author":"Luo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.5120","article-title":"Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter\u22121 and lactate dehydrogenase A","volume":"57","author":"Xu","year":"2020","journal-title":"Int J Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2017.10.027","article-title":"NLRP3 inflammasome pathways in atherosclerosis","volume":"267","author":"Baldrighi","year":"2017","journal-title":"Atherosclerosis"},{"key":"B88","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.1463-1326.2010.01336.x","article-title":"Diabetes is an inflammatory disease: evidence from traditional Chinese medicines","volume":"13","author":"Xie","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"B89","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2021.03.004","article-title":"Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy","volume":"82","author":"Borzouei","year":"2021","journal-title":"Hum Immunol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.820541","article-title":"Canagliflozin ameliorates NLRP3 inflammasome-mediated inflammation through inhibiting NF-\u03baB signaling and upregulating bif-1","volume":"13","author":"Niu","year":"2022","journal-title":"Front Pharmacol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12933-024-02298-9","article-title":"Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure","volume":"23","author":"Kasperova","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1413935112","article-title":"Essential role for autophagy during invariant NKT cell development","volume":"111","author":"Salio","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11040712","article-title":"The protective effect of sericin on AML12 cells exposed to oxidative stress damage in a high-glucose environment","volume":"11","author":"Jing","year":"2022","journal-title":"Antioxids (Basel)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897047","article-title":"Enhanced T cell glucose uptake is associated with progression of beta-cell function in type 1 diabetes","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.836849","article-title":"Emerging roles of sodium glucose cotransporter 2 (SGLT-2) inhibitors in diabetic cardiovascular diseases: focusing on immunity, inflammation and metabolism","volume":"13","author":"Xie","year":"2022","journal-title":"Front Pharmacol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18293","article-title":"Empagliflozin modulates CD4(+) T-cell differentiation via metabolic reprogramming in immune thrombocytopenia","volume":"198","author":"Qin","year":"2022","journal-title":"Br J Haematol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study","volume":"20","author":"Hiruma","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05128-8","article-title":"Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19","volume":"609","author":"Karagiannis","year":"2022","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e14323","DOI":"10.15252\/emmm.202114323","article-title":"Very-low-carbohydrate diet enhances human T-cell immunity through immunometabolic reprogramming","volume":"13","author":"Hirschberger","year":"2021","journal-title":"EMBO Mol Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012325","article-title":"Repurposing SGLT-2 inhibitors to target aging: available evidence and molecular mechanisms","volume":"23","author":"La Grotta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073351","article-title":"Mitochondrial changes induced by SGLT2i in lymphocytes from diabetic kidney transplant recipients: A pilot study","volume":"26","author":"P\u00e9rez-Flores","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0058","article-title":"The na+\/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"18025","DOI":"10.1038\/s41598-023-45390-y","article-title":"Empagliflozin induces the transcriptional program for nutrient homeostasis in skeletal muscle in normal mice","volume":"13","author":"Kawakami","year":"2023","journal-title":"Sci Rep"},{"key":"B108","doi-asserted-by":"publisher","first-page":"111038","DOI":"10.1016\/j.intimp.2023.111038","article-title":"Dapagliflozin attenuates the vulnerability to atrial fibrillation in rats with lipopolysaccharide-induced myocardial injury","volume":"125","author":"Zhao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"114830","DOI":"10.1016\/j.bbr.2023.114830","article-title":"Empagliflozin alleviates diabetes-induced cognitive impairments by lowering nicotinamide adenine dinucleotide phosphate oxidase-4 expression and potentiating the antioxidant defense system in brain tissue of diabetic rats","volume":"460","author":"Yaribeygi","year":"2024","journal-title":"Behav Brain Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12933-024-02477-8","article-title":"ALDH2 mediates the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on improving cardiac remodeling","volume":"23","author":"Liu","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12056","article-title":"The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus","volume":"76","author":"Kasichayanula","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab Res Rev"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1641699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:44Z","timestamp":1759119164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1641699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":118,"alternative-id":["10.3389\/fendo.2025.1641699"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1641699","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1641699"}}